The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.
Alzheimer's disease (AD) is a multifactorial neurological disorder with no current cure, creating a significant medical demand. Traditional theories attribute AD to the build-up of the toxic protein amyloid beta (Aβ) and the formation of neurofibrillary tangles of tau-protein. However, emerging evidence propose that impaired mitochondrial function and metabolic activity play a crucial role in AD's development and progression. Our laboratory's primary focus is to explore and uncover effective methods for preventing and treating Alzheimer's disease. To achieve this, we apply different cutting
The purpose of this study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis (Study Device) when used for the treatment of Abdominal Aortic Aneurysms (AAA).
The purpose of this clinical trial is to trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals not responding to their current treatment.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
PURPOSE: This is a biological sample collection study aimed at developing an early diagnostic tool for endometrial and ovarian cancer. The investigators are studying the relationship between estrogen driven gynecological cancers, inflammation and the microbiome. Patients who have been diagnosed with endometrial cancer or undergo presurgical evaluation for suspicion of ovarian cancer who are scheduled for a hysterectomy, bilateral oophorectomy and/or salpingectomy are eligible. Control patients undergoing gynecological surgery for benign indications are also being recruited.
